SG
ABBV icon

Swarthmore Group’s AbbVie ABBV Stock Holding History

Swarthmore Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$624K Sell
4,076
-51,224
-93% -$7.83M 0.25% 7
2022
Q1 		$8.96M Sell
55,300
-592
-1% -$86K 2.29% 7
2021
Q4 		$7.57M Buy
+55,892
New +$6.6M 1.8% 17
2018
Q1 		– Sell
-3,275
Closed -$317K – 33
2017
Q4 		$317K Sell
3,275
-350
-10% -$33K 0.07% 45
2017
Q3 		$322K Buy
+3,625
New +$276K 0.07% 48
2016
Q4 		– Sell
-342,350
Closed -$21.6M – 52
2016
Q3 		$21.6M Sell
342,350
-7,850
-2% -$508K 4.13% 6
2016
Q2 		$21.7M Sell
350,200
-97,850
-22% -$5.96M 3.68% 7
2016
Q1 		$25.6M Sell
448,050
-160,500
-26% -$8.95M 3.91% 8
2015
Q4 		$36.1M Sell
608,550
-54,200
-8% -$3.12M 3.86% 10
2015
Q3 		$36.1M Buy
662,750
+5,000
+0.8% +$325K 3.83% 11
2015
Q2 		$44.2M Sell
657,750
-56,925
-8% -$3.72M 4.11% 6
2015
Q1 		$41.8M Sell
714,675
-23,300
-3% -$1.41M 3.81% 8
2014
Q4 		$48.3M Sell
737,975
-24,175
-3% -$1.52M 4.38% 7
2014
Q3 		$44M Buy
762,150
+108,725
+17% +$6.04M 4.08% 5
2014
Q2 		$36.9M Sell
653,425
-17,950
-3% -$942K 3.88% 7
2014
Q1 		$34.5M Buy
671,375
+53,250
+9% +$2.69M 4.08% 8
2013
Q4 		$32.6M Sell
618,125
-12,150
-2% -$597K 3.8% 10
2013
Q3 		$28.2M Buy
630,275
+9,500
+2% +$421K 3.61% 17
2013
Q2 		$25.7M Buy
+620,775
New +$27.1M 3.25% 18

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Swarthmore Group's ABBV Position: Q2 2022 in Review

Swarthmore Group reduced its AbbVie (ABBV) stake by 93% in Q2 2022, selling an estimated $7.83M and leaving 4,076 shares worth $624K. The position accounts for 0.25% of the portfolio, ranked #7.

Swarthmore Group first reported a position in ABBV in Q2 2013 and has held it in 19 quarters since. The position peaked at $48.3M in Q4 2014. 3,005 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

  • Swarthmore Group held 4,076 shares of AbbVie worth $624K as of Q2 2022.
  • Swarthmore Group sold 51,224 AbbVie shares in Q2 2022, an estimated $7.83M.
  • AbbVie made up 0.25% of Swarthmore Group's portfolio in Q2 2022, its #7 holding.
  • Swarthmore Group first reported a position in AbbVie in Q2 2013 and has held it in 19 quarters since.
  • Swarthmore Group's AbbVie position peaked at $48.3M in Q4 2014.
  • 3,005 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Swarthmore Group's 13F filing for Q2 2022, filed 20 Jul 2022.